[go: up one dir, main page]

CA3191452A1 - Composes d'acide azacyclohexyle acetique substitues par triazole-pyridinyle utilises en tant qu'antagonistes du recepteur lpa - Google Patents

Composes d'acide azacyclohexyle acetique substitues par triazole-pyridinyle utilises en tant qu'antagonistes du recepteur lpa

Info

Publication number
CA3191452A1
CA3191452A1 CA3191452A CA3191452A CA3191452A1 CA 3191452 A1 CA3191452 A1 CA 3191452A1 CA 3191452 A CA3191452 A CA 3191452A CA 3191452 A CA3191452 A CA 3191452A CA 3191452 A1 CA3191452 A1 CA 3191452A1
Authority
CA
Canada
Prior art keywords
compound
substituted
ring
occurrence
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3191452A
Other languages
English (en)
Inventor
Hongjian Zhang
Ping Chen
Zhenwei CAI
Fei Jiang
Peihua Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viva Star Biosciences Ltd
Original Assignee
Viva Star Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viva Star Biosciences Ltd filed Critical Viva Star Biosciences Ltd
Publication of CA3191452A1 publication Critical patent/CA3191452A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention concerne des nouveaux composés d'acide azacyclohexyl acétique substitués, leur fabrication, des compositions pharmaceutiques les comprenant, ainsi que leur utilisation en tant que médicaments pour traiter une maladie associée à une dysrégulation des récepteurs de l'acide lysophosphatidique (LPA).
CA3191452A 2020-08-11 2021-10-09 Composes d'acide azacyclohexyle acetique substitues par triazole-pyridinyle utilises en tant qu'antagonistes du recepteur lpa Pending CA3191452A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/108325 2020-08-11
CN2020108325 2020-08-11
PCT/IB2021/059266 WO2022034568A1 (fr) 2020-08-11 2021-10-09 Composés d'acide azacyclohexyle acétique substitués par triazole-pyridinyle utilisés en tant qu'antagonistes du récepteur lpa

Publications (1)

Publication Number Publication Date
CA3191452A1 true CA3191452A1 (fr) 2022-02-17

Family

ID=78179477

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3191452A Pending CA3191452A1 (fr) 2020-08-11 2021-10-09 Composes d'acide azacyclohexyle acetique substitues par triazole-pyridinyle utilises en tant qu'antagonistes du recepteur lpa

Country Status (9)

Country Link
EP (1) EP4196220A1 (fr)
JP (1) JP2023544476A (fr)
KR (1) KR20240068583A (fr)
CN (1) CN116669727B (fr)
AU (1) AU2021323515A1 (fr)
CA (1) CA3191452A1 (fr)
IL (1) IL300525A (fr)
MX (1) MX2023001812A (fr)
WO (1) WO2022034568A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
AU2021282986B2 (en) 2020-06-03 2024-03-07 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
EP4330249A1 (fr) * 2021-04-30 2024-03-06 Viva Star Biosciences (Suzhou) Co., Ltd. Nouveaux composés d'acide pyrrolidinyl et tétrahydro-2 h-pyranyl acétique à substitution par triazole-pyridine utilisés en tant qu'antagonistes de lpa
KR20240005892A (ko) 2021-05-11 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
AU2022405082B2 (en) 2021-12-08 2025-09-25 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物
TW202417426A (zh) * 2022-07-25 2024-05-01 大陸商武漢人福創新藥物研發中心有限公司 三氮唑類化合物及其作為lpar1拮抗劑的用途
WO2025051266A1 (fr) * 2023-09-08 2025-03-13 西藏海思科制药有限公司 Antagoniste de lpar1 dérivé d'un dérivé hétéroaromatique et son utilisation
WO2025162421A1 (fr) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 Antagoniste de lpar1 et son utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234318D1 (de) * 2001-02-08 2009-12-24 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
DK2443248T3 (en) * 2009-06-16 2018-03-12 Du Pont IMPROVEMENT OF LONG-CHAIN POLYUM Saturated OMEGA-3 AND OMEGA-6 FATTY ACID BIOS SYNTHESIS BY EXPRESSION OF ACYL-CoA LYSOPHOSPHOLIPID ACYL TRANSFERASES
US8785442B2 (en) * 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
WO2012138648A1 (fr) * 2011-04-06 2012-10-11 Irm Llc Compositions et procédés pour la modulation de récepteurs au lpa
EP2922823B1 (fr) 2012-11-20 2018-10-31 Merck Sharp & Dohme Corp. Inhibiteurs pyrimidines de pde10
US20140200215A1 (en) * 2013-01-15 2014-07-17 Intermune, Inc. Lysophosphatidic acid receptor antagonists
SG11201507459YA (en) * 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
WO2019126087A1 (fr) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Acide cyclohexyle isoxazole azoles en tant qu'antagonistes de lpa
US11261174B2 (en) * 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists
CA3085938A1 (fr) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Azoles triazoles d'acide cyclohexyle utilises en tant qu'antagonistes de lpa
ES2936517T3 (es) * 2017-12-19 2023-03-17 Bristol Myers Squibb Co Triazol azinas de ácido ciclohexílico como antagonistas de LPA
US12209072B2 (en) * 2018-09-18 2025-01-28 Bristol-Myers Squibb Company Cyclopentyl acids as LPA antagonists

Also Published As

Publication number Publication date
JP2023544476A (ja) 2023-10-24
CN116669727B (zh) 2025-07-08
WO2022034568A1 (fr) 2022-02-17
IL300525A (en) 2023-04-01
AU2021323515A1 (en) 2023-03-09
MX2023001812A (es) 2023-06-19
KR20240068583A (ko) 2024-05-17
CN116669727A (zh) 2023-08-29
EP4196220A1 (fr) 2023-06-21

Similar Documents

Publication Publication Date Title
CA3191452A1 (fr) Composes d'acide azacyclohexyle acetique substitues par triazole-pyridinyle utilises en tant qu'antagonistes du recepteur lpa
CA3124898C (fr) Intermediaire de compose heterocyclique, son procede de preparation et son utilisation
AU2007311591B2 (en) Biaryl ether urea compounds
JP7577655B2 (ja) 環状尿素
CA3085561A1 (fr) Azines triazoles d'acide cyclohexyle utilisees en tant qu'antagonistes de lpa
BR112016011024B1 (pt) Composto, composição farmacêutica, e, usos dos mesmos
WO2013066729A1 (fr) Aminopyrimidinones en tant qu'inhibiteurs de kinases associées au récepteur de l'interleukine
EP4333899A1 (fr) Composés destinés à cibler la dégradation de la tyrosine kinase de bruton
EP4284365A1 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
JP2024537110A (ja) Ｅｎｔ１阻害活性を有する大環状化合物
CA3218258A1 (fr) Nouveaux composes d'acide pyrrolidinyl et tetrahydro-2 h-pyranyl acetique a substitution par triazole-pyridine utilises en tant qu'antagonistes de lpa
WO2024026483A2 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
IL296602A (en) n-(Heterocyclyl and heterocyclylalkyl)-3-benzylpyridine-2-amine derivatives as sstr4 agonists
WO2023086521A1 (fr) Inhibiteurs de btk